Clinical trials: Pregnancy Complications, Infectious
HIV Infections, Pregnancy
Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
PRIMARY: To evaluate the short-term safety of rgp120/HIV-1SF2 vaccine versus MF59 placebo administered to HIV-infected pregnant women.
- Conditions
- HIV Infections, Pregnancy, HIV Seronegativity
- Trial name
- NCT00001046
- Testing
- MF59, rgp120/HIV-1 SF-2
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children
AMENDED: To evaluate the pharmacokinetics of intravenously administered AZT to HIV-1 infected pregnant women in labor; to evaluate the pharmacokinetics and urinary excretion of AZT and its metabolites in newborns of HIV-1…
- Trial name
- NCT00001106
- Testing
- Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby during delivery.
- Trial name
- NCT00001135
- Testing
- Nevirapine
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 2,009 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months
The purpose of this study is to see if it is safe to give nevirapine (NVP) to breast-feeding babies from birth to the age of 6 months and to determine what dose of NVP should be given.
- Trial name
- NCT00006279
- Testing
- Nevirapine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
The best anti-HIV treatment regimen for pregnant women is not known. Protease inhibitors (PIs) are often used, but they have side effects that may be harmful for pregnant women.
- Trial name
- NCT00017719
- Testing
- Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate
- Where
- 49 sites in United States, Brazil and 2 more
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women
To assess the pharmacokinetics, safety, and toxicity of intravenous and oral didanosine (ddI) administration in third trimester pregnant women who are HIV positive but are either intolerant or resistant to zidovudine (AZT).
- Trial name
- NCT00000839
- Testing
- Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to evaluate the safety and tolerance of 2 anti-HIV drugs, d4T and 3TC, given in combination to HIV-positive pregnant women and their infants.
- Trial name
- NCT00000878
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe.
- Trial name
- NCT00000879
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205)
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe.
- Trial name
- NCT00000887
- Testing
- Nelfinavir mesylate, Lamivudine, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth.
- Trial name
- NCT00000888
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery.
- Trial name
- NCT00000942
- Testing
- Nevirapine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 1,244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from…
- Trial name
- NCT00000944
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants
To determine whether the rate of HIV transmission from mother to infant can be reduced by continuous oral zidovudine (AZT) treatment to HIV infected pregnant women, intravenous AZT during childbirth, and oral AZT treatment of the…
- Trial name
- NCT00000960
- Testing
- Zidovudine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 1,496 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
To evaluate the safety of gp160 vaccine (VaxSyn) in HIV-1 infected pregnant women with CD4 counts >= 400 cells/mm3. To evaluate the immunogenicity of this vaccine in pregnant women and the passive acquisition of vaccine-specific…
- Conditions
- HIV Infections, Pregnancy, HIV Seronegativity
- Trial name
- NCT00000777
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women
To obtain a pharmacokinetic profile of oral ZDV and to determine whether the oral administration of Zidovudine (ZDV) during labor and delivery will provide a similar profile to that obtained with the use of IV ZDV in ACTG 082.
- Trial name
- NCT00000862
- Testing
- Zidovudine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women
The purpose of this study is to determine the safety, tolerance, and metabolism of single-dose and multiple-dose abacavir (ABC) in HIV-exposed infants receiving standard postnatal treatment with zidovudine (ZDV).
- Trial name
- NCT00000864
- Testing
- Abacavir sulfate, Zidovudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery.
- Trial name
- NCT00000869
- Testing
- Nevirapine
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 2,009 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Maternal Sepsis, Intensive Care Units
Epidemiological Investigation of Sepsis in Obstetrics Admitted to ICU
Sepsis is still the main cause of maternal death, accounting for 11% of maternal deaths. Early identification of high risk factors of sepsis and early intervention can improve the prognosis of pregnant women with sepsis.
- Conditions
- Maternal Sepsis, Intensive Care Units, Drug Resistance, Multiple
- Trial name
- NCT05055388
- Testing
- Multidrug-resistant bacteria
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University Third Hospital
Sepsis, Maternal Sepsis
mSEP: Testing of Physiological and Immune-metabolic Blood Markers for Maternal Sepsis
A prospective observational cohort study investigating physiological parameters vs biological markers of whole blood in septic and non-septic pregnant woman to predict systemic immune health
- Conditions
- Sepsis, Maternal Sepsis, Maternal Sepsis During Labor, SIRS
- Trial name
- NCT05023954
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Cardiff University
Pregnancy, Infections in, Covid19
Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies
Complete blood count parameters are routinely evaluated cost-effective markers in diagnosis and clinical follow-up of infectious diseases.There is increasing number of studies to report the course of COVID-19 in pregnancy.
- Trial name
- NCT04515108
- Testing
- Clinical assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent